Standing with the Cancer Survivor Community on Rare Disease Day

Ringing the bell at the end of cancer treatment is not the end of the journey for many of the 18 million cancer survivors in the United States. Treating cancer is a highly complex process and a balancing act between effectively targeting and eliminating cancer cells, while minimizing harm to healthy tissue and organs.

The number of people living with the long term effects of cancer treatment continues to rise. Those who have received radiation or chemotherapy for prostate, colon, uterine, cervical and other pelvic cancers are at risk of developing hemorrhagic cystitis, a rare, serious and painful condition, months and even years after treatment has been completed.

Lipella is committed to supporting patients who have faced serious health challenges and are now met with another. We are evaluating LP-10 for the treatment of hemorrhagic cystitis. It is an outstanding drug candidate with established safety and efficacy, and in Lipella’s clinical studies, it has demonstrated decreased bleeding and ulceration, and improved urinary symptoms in patients.

A second rare complication following cancer treatment is Graft-versus-Host Disease (GvHD), a systemic disorder in which the immune cells of donated or transplanted tissue recognize the host as foreign, and attack the recipient's cells. Lipella is developing LP-410 for the treatment of oral GvHD which causes significant pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD currently has no FDA approved treatment, and can severely impact a patient's quality of life.

Lipella is committed to advancing LP-10 and LP-410 through the regulatory process as expeditiously as possible. Our mission is to develop safe and effective treatments for these rare diseases, bringing hope to those who need it the most.

Dr. Michael Chancellor

Chief Medical Officer

Lipella Pharmaceuticals